News

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and prediction of treatment response.

At RSNA 2016, Mint Medical showcases a comprehensive set of new criteria including mRECIST mesothelioma, the Lugano (Cheson 2014 lymphoma) Classification, the Prostate Cancer Working Group (PCWG2) criteria, and iRECIST.

As an example, immune-related therapies can show tumor growth from treatment effect rather than true disease progression (“pseudoprogression”). mint Lesion™ 3.3 now supports the iRECIST criteria as currently drafted by the RECIST working group. iRECIST is the first immune-related criteria distinguishing between an unconfirmed and a confirmed Progressive Disease (PD).

Therapy Response Assessment iRECIST

Related Resources

Related Resources

Scientifically proven benefits of mint Lesion™ in clinical routine

In contrast to clinical trials, unstructured free-text reporting is still common in the clinical routine. Such reports often lack content and clarity,…

Raising our awareness in pediatric cancer

The terms rare, uncommon, infrequent are commonly used to describe the occurrence of cancer in children –  from a prevalence perspective, “only”…

Enhancing flexibility and communication while saving costs and time in clinical trials

Emily Ferris and Alex Arbuckle describe how using mint Lesion™ has enhanced their clinical trial operations, enabling “a more cooperative approach…